Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a
biopharmaceutical company utilizing sophisticated computational
methods to design de novo protein therapeutics, today
announced three presentations at the American Association for
Cancer Research (AACR) Virtual Annual Meeting II taking place June
22-24, 2020. The presentations include preclinical data on lead
candidate NL-201, as well as other applications of Neoleukin’s de
novo protein design platform.
Abstract #4518, a poster presentation, will feature preclinical
data on NL-201, an IL-2 and IL-15 agonist designed to eliminate
alpha binding for therapeutic use in cancer. Details of the
structure and characteristics of the extended half-life molecule,
in vivo activity in multiple tumor models, immunogenicity data in
non human primates, and pharmacodynamic effects will be
presented.
Abstract #1075, a minisymposium presentation, will highlight a
conditional activation approach for de novo proteins, demonstrating
the ability to split Neo-2/15 into two inactive pieces and to
reconstitute binding and signaling when co-targeted to the tumor
cell surface in preclinical models. This represents a novel method
for conditional activation, made possible by Neoleukin’s
computational technology and engineered stability of de novo
proteins. This presentation is in collaboration with the Institute
for Protein Design at the University of Washington.
Abstract #2222, a poster presentation, will describe engineered
variants of Neo-2/15 that demonstrate the ability to induce robust
CAR-T cell expansion as well as enhance CAR-T antitumor activity in
preclinical models. This poster is presented in collaboration with
investigators at the Fred Hutchinson Cancer Research Center.
“These AACR presentations highlight the exciting potential of
our de novo protein design technology. This includes significant
information on our lead candidate, NL-201, which we are advancing
toward clinical testing,” said Jonathan Drachman, M.D., Chief
Executive Officer of Neoleukin. “Our presentations also describe a
novel approach to conditional activation, which has the potential
to widen the therapeutic index of potent immunotherapies. We
believe that the split molecule approach is particularly
well-suited to de novo protein design due to enhanced
stability.”
Following the AACR Virtual Annual Meeting II, Neoleukin will
host a virtual investor event to further discuss NL-201 and
applications of de novo protein design technology. Details
regarding the event will be announced at a future date.
Minisymposum Presentation
Title: Conditionally active de
novo IL-2 cytokine mimetics for targeted
immunotherapy: de novo split technology
Lead Author: Alfredo
Quijano-Rubio, University of Washington, Institute for
Protein Design
Abstract Number: 1075Session
Category: ImmunologySession
Title: Immunomodulatory Agents and
InterventionsFormat: 10 minute presentation
followed by question and answer sessionDate &
Time: Tuesday, June 23, 2020, 9 a.m. to 11 a.m. Eastern
TimeURL:
https://www.abstractsonline.com/pp8/#!/9045/presentation/6914
Poster Presentations
Title: Pre-clinical development of NL-201:
A de novo α-independent IL-2/IL-15 agonist
Lead Author: Carl Walkey, Ph.D., Neoleukin
TherapeuticsAbstract Number: 4518Session
Category: ImmunologySession Title:
Immunomodulatory Agents and Interventions 1Format:
Poster accompanied by audio
descriptionURL:
https://www.abstractsonline.com/pp8/#!/9045/presentation/7499
Title: Engineered variants of Neo-2/15 potently
expand CAR-T cells and promote antitumor activity in lymphoma and
solid tumor mouse models
Lead Author: Isabel Leung, Ph.D., Fred
Hutchinson Cancer Research Center, Division of Clinical
ResearchAbstract Number: 2222Session
Category: ImmunologySession Title:
Combination Immunotherapies 2Format:
Poster accompanied by audio
descriptionURL:
https://www.abstractsonline.com/pp8/#!/9045/presentation/7198
About Neoleukin Therapeutics, Inc.
Neoleukin is a biopharmaceutical company creating next
generation immunotherapies for cancer, inflammation and
autoimmunity using de novo protein design technology.
Neoleukin uses sophisticated computational methods to design
proteins that demonstrate specific pharmaceutical properties that
provide potentially superior therapeutic benefit over native
proteins. Neoleukin’s lead product candidate, NL-201, is a
combined IL-2 and IL-15 agonist designed to improve tolerability
and activity by eliminating the alpha receptor binding interface.
For more information, please visit the Neoleukin
website: www.neoleukin.com.
Safe Harbor / Forward-Looking
Statements
This press release contains "forward-looking" statements within
the meaning of the safe harbor provisions of the U.S. Private
Securities Litigation Reform Act of 1995, including, but not
limited to, planned development activities and timelines, use and
adequacy of cash reserves and the potential benefits of the
company’s product candidates and platform. Forward-looking
statements can be identified by words such as: "anticipate,"
"intend," "plan," "goal," "seek," "believe," "project," "estimate,"
"expect," "strategy," "future," "likely," "may," "should," "will"
and similar references to future periods. Examples of such
forward-looking statements include but are not limited to
statements regarding the therapeutic properties and potential of
the company’s de novo protein design technology. These statements
are subject to numerous risks and uncertainties, including risks
and uncertainties related to the company’s cash forecasts, the
company’s ability to advance its product candidates, the receipt
and timing of potential regulatory submissions, designations,
approvals and commercialization of product candidates, the timing
and results of preclinical and clinical trials, the timing of
announcements and updates relating to the company’s clinical trials
and related data market conditions and further impacts of COVID-19,
that could cause actual results to differ materially from what
Neoleukin expects. Further information on potential risk factors
that could affect Neoleukin’s business and its financial results
are detailed under the heading “Risk Factors” in documents the
company files from time to time with the Securities and
Exchange Commission (SEC), and other reports as filed with
the SEC. Neoleukin undertakes no obligation to publicly update
any forward-looking statement, whether written or oral, that may be
made from time to time, whether as a result of new information,
future developments or otherwise.
Contacts:
MediaJulie
Rathbun206-769-9219jrathbun@neoleukin.com
InvestorsSolebury TroutBrian Korb646-378-2923bkorb@troutgroup.com
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Neoleukin Therapeutics (NASDAQ:NLTX)
Historical Stock Chart
From Jul 2023 to Jul 2024